• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

中国新疆地区 HIV 长期非进展者的生存分析及免疫差异：一项为期 12 年的前瞻性队列观察。

Survival Analysis and Immune Differences of HIV Long-Term Non-progressors in Xinjiang China: A 12-Year Prospective Cohort Observation.

机构信息

Public Health School, Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.

STD/HIV Prevention and Control Center, Xinjiang Uighur Autonomous Region Center for Disease Control and Prevention, Urumqi, 830002, Xinjiang, China.

出版信息

AIDS Behav. 2024 Sep;28(9):3151-3160. doi: 10.1007/s10461-024-04396-x. Epub 2024 Jun 13.

DOI:10.1007/s10461-024-04396-x
PMID:38869754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11390762/
Abstract

This 12-year cohort study of 80 long-term non-progressors (LTNPs) observed a cumulative follow-up duration of 628.5 person-years. Among them, 60 received antiretroviral therapy (ART) for a total of 418.6 person-years. Twenty-four deaths occurred during the follow-up period, with an average age of 42.36 years and a lowest 8-year survival rate of 0.90. Cox model analysis revealed that the risk of AIDS-related death was 1.47 times higher for non-marital, non-commercial heterosexual transmission than for injection drug use. Treatment initiation at ages 31-40 was correlated with an elevated risk of mortality, while treatment for 3-10 years reduced mortality risks in untreated LTNPs. Flow cytometry observed significant differences in the proportion of NK cells. Long-term ART (> 2 years) before LTNPs developed AIDS symptoms could lower mortality risk and potentially extend lifespan, especially when it was initiated at a younger age without affecting NK cell balance. Epidemiological and immunological studies on ART-treated LTNPs are vital for advancing HIV treatment and achieving functional cures for AIDS individuals.

摘要

本研究对 80 名长期非进展者（LTNPs）进行了 12 年的队列研究，观察到累积随访时间为 628.5 人年。其中 60 人接受了抗逆转录病毒治疗（ART），总共有 418.6 人年。在随访期间发生了 24 例死亡，平均年龄为 42.36 岁，最低 8 年生存率为 0.90。Cox 模型分析表明，非婚姻、非商业异性传播的艾滋病相关死亡风险是非注射吸毒者的 1.47 倍。31-40 岁开始治疗与死亡率升高相关，而在未治疗的 LTNPs 中，治疗 3-10 年可降低死亡率。流式细胞术观察到 NK 细胞比例有显著差异。在出现艾滋病症状之前，LTNPs 接受长期 ART（>2 年）治疗可以降低死亡率风险，并可能延长寿命，特别是在不影响 NK 细胞平衡的情况下，在较年轻的时候开始治疗。对接受 ART 治疗的 LTNPs 的流行病学和免疫学研究对于推进 HIV 治疗和实现艾滋病个体的功能性治愈至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/13bdd2f7254f/10461_2024_4396_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/b83088a653ae/10461_2024_4396_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/115716165c39/10461_2024_4396_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/aaedfbef209b/10461_2024_4396_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/13bdd2f7254f/10461_2024_4396_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/b83088a653ae/10461_2024_4396_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/115716165c39/10461_2024_4396_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/aaedfbef209b/10461_2024_4396_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7981/11390762/13bdd2f7254f/10461_2024_4396_Fig4_HTML.jpg

相似文献

1
Survival Analysis and Immune Differences of HIV Long-Term Non-progressors in Xinjiang China: A 12-Year Prospective Cohort Observation.中国新疆地区 HIV 长期非进展者的生存分析及免疫差异：一项为期 12 年的前瞻性队列观察。
AIDS Behav. 2024 Sep;28(9):3151-3160. doi: 10.1007/s10461-024-04396-x. Epub 2024 Jun 13.
2
Effect of antiretroviral therapy on the mortality of HIV-1 infection long-term non-progressors: a cohort study.抗逆转录病毒疗法对HIV-1感染长期不进展者死亡率的影响：一项队列研究。
BMC Infect Dis. 2025 Jan 16;25(1):72. doi: 10.1186/s12879-025-10448-x.
3
[Study on the mortality and risk factors among HIV/AIDS patients receiving antiretroviral therapy in Xinjiang Uygur Autonomous Region].新疆维吾尔自治区接受抗逆转录病毒治疗的艾滋病患者死亡率及危险因素研究
Zhonghua Yu Fang Yi Xue Za Zhi. 2014 Nov;48(11):953-8.
4
Higher Risks of Virologic Failure and All-Cause Deaths Among Older People Living with HIV in Chongqing, China.中国重庆老年HIV感染者病毒学失败和全因死亡风险更高。
AIDS Res Hum Retroviruses. 2019 Nov/Dec;35(11-12):1095-1102. doi: 10.1089/AID.2019.0096. Epub 2019 Oct 29.
5
Demographic and clinical factors correlated with clinical outcomes among people with HIV treated by antiretroviral therapy: a retrospective cohort study.人口统计学和临床因素与接受抗逆转录病毒治疗的 HIV 感染者的临床结局相关：一项回顾性队列研究。
BMC Infect Dis. 2024 May 22;24(1):514. doi: 10.1186/s12879-024-09406-w.
6
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.高效抗逆转录病毒疗法对感染HIV的儿童和青少年生存的长期有效性：一项10年随访研究
Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.
7
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.早期和长期的抗逆转录病毒治疗与 HIV-1 特异性 T 细胞表型相关，类似于长期非进展者的表型。
PLoS One. 2011 Apr 5;6(4):e18164. doi: 10.1371/journal.pone.0018164.
8
[Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region].[新疆维吾尔自治区接受抗逆转录病毒治疗的艾滋病患者的性别特异性死亡率及危险因素]
Zhonghua Liu Xing Bing Xue Za Zhi. 2015 Sep;36(9):971-5.
9
[Analysis on 10 year survival of HIV/AIDS patients receiving antiretroviral therapy during 2003-2005 in Henan province].[河南省2003 - 2005年接受抗逆转录病毒治疗的艾滋病病毒/艾滋病患者10年生存情况分析]
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Jul 10;39(7):966-970. doi: 10.3760/cma.j.issn.0254-6450.2018.07.019.
10
The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.注射吸毒史对开始联合抗逆转录病毒治疗的 HIV 阳性个体疾病进展和死亡的影响：合作队列分析。
HIV Med. 2012 Feb;13(2):89-97. doi: 10.1111/j.1468-1293.2011.00940.x. Epub 2011 Aug 7.

引用本文的文献

1
Survival analysis of PLWH on antiretroviral therapy in Henan Province from 2004 to 2024.2004年至2024年河南省接受抗逆转录病毒治疗的艾滋病毒感染者生存分析
Sci Rep. 2025 Jul 1;15(1):21322. doi: 10.1038/s41598-025-05821-4.
2
Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination.用于艾滋病毒预防和控制的生物医学干预措施：超越疫苗接种
Viruses. 2025 May 26;17(6):756. doi: 10.3390/v17060756.
3
Machine learning-based prediction of mortality risk in AIDS patients with comorbid common AIDS-related diseases or symptoms.基于机器学习对合并常见艾滋病相关疾病或症状的艾滋病患者死亡风险的预测

本文引用的文献

1
Elite and viremic HIV-1 controllers in West Africa.西非的精英控制者和病毒血症 HIV-1 感染者。
AIDS. 2022 Jan 1;36(1):29-38. doi: 10.1097/QAD.0000000000003072.
2
How elite controllers and posttreatment controllers inform our search for an HIV-1 cure.精英控制者和治疗后控制者如何帮助我们寻找 HIV-1 治愈方法。
J Clin Invest. 2021 Jun 1;131(11). doi: 10.1172/JCI149414.
3
High rates of long-term progression in HIV-1-positive elite controllers.HIV-1 阳性精英控制者中存在较高的长期进展率。
Front Public Health. 2025 Mar 12;13:1544351. doi: 10.3389/fpubh.2025.1544351. eCollection 2025.
J Int AIDS Soc. 2021 Feb;24(2):e25675. doi: 10.1002/jia2.25675.
4
Life expectancy of HIV-infected patients followed at the largest hospital in Guinea-Bissau is one-fourth of life expectancy of the background population.在几内亚比绍最大的医院接受治疗的 HIV 感染者的预期寿命是该背景人群预期寿命的四分之一。
Infection. 2021 Aug;49(4):631-643. doi: 10.1007/s15010-020-01574-6. Epub 2021 Feb 2.
5
Antiretroviral Treatment for HIV Elite Controllers?针对HIV精英控制者的抗逆转录病毒治疗？
Pathog Immun. 2020 May 19;5(1):121-133. doi: 10.20411/pai.v5i1.364. eCollection 2020.
6
Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.队列研究中既往 HIV 控制者病毒迅速失控的机制。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01436-18. Print 2019 Feb 15.
7
Telomere length correlates with disease severity and inflammation in sickle cell disease.端粒长度与镰状细胞病的疾病严重程度和炎症相关。
Rev Bras Hematol Hemoter. 2017 Apr-Jun;39(2):140-145. doi: 10.1016/j.bjhh.2017.02.007. Epub 2017 Mar 11.
8
Inflammation, Immune Activation, and Antiretroviral Therapy in HIV.HIV感染中的炎症、免疫激活与抗逆转录病毒疗法
Curr HIV/AIDS Rep. 2017 Jun;14(3):93-100. doi: 10.1007/s11904-017-0356-x.
9
Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.肠道黏膜屏障功能障碍、微生物群失调及其在HIV-1疾病进展中的作用。
J Infect Dis. 2016 Oct 1;214 Suppl 2(Suppl 2):S58-66. doi: 10.1093/infdis/jiw258.
10
HIV and ageing: improving quantity and quality of life.艾滋病病毒与衰老：改善生活质量与数量
Curr Opin HIV AIDS. 2016 Sep;11(5):527-536. doi: 10.1097/COH.0000000000000305.